A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer

Pautier, Patricia; Vergote, Ignace; Joly, Florence; Melichar, Bohuslav; Kutarska, Elzbieta; Hall, Geoffrey; Lisyanskaya, Anna; Reed, Nicholas; Oaknin, Ana; Ostapenko, Valerijus; Zvirbule, Zanete; Chetaille, Eric; Geniaux, Agnès; Shoaib, Muhammad; Green, John A

doi:10.1097/IGC.0000000000000862

A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer

Author:

Pautier, Patricia

Vergote, Ignace ; Joly, Florence ; Melichar, Bohuslav ; Kutarska, Elzbieta ; Hall, Geoffrey ; Lisyanskaya, Anna ; Reed, Nicholas ; Oaknin, Ana ; Ostapenko, Valerijus ; Zvirbule, Zanete ; Chetaille, Eric ; Geniaux, Agnès ; Shoaib, Muhammad ; Green, John A

Keywords:

Science & Technology, Life Sciences & Biomedicine, Oncology, Obstetrics & Gynecology, Advanced/recurrent endometrial cancer, Hormone therapy, Irosustat, Megestrol acetate, Overall survival, Progression-free survival, GYNECOLOGIC-ONCOLOGY-GROUP, STEROID SULFATASE INHIBITORS, BREAST-CANCER, ENDOCRINE THERAPY, CLINICAL-TRIALS, II TRIAL, CARCINOMA, RECURRENT, ESTROGEN, CARBOPLATIN, Aged, Antineoplastic Agents, Hormonal, Disease-Free Survival, Endometrial Neoplasms, Female, Humans, Megestrol Acetate, Neoplasm Recurrence, Local, Receptors, Estrogen, Sulfonic Acids, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, 3202 Clinical sciences, 3211 Oncology and carcinogenesis

Abstract:

Advanced/metastatic or recurrent endometrial cancer has a poor prognosis. Malignant endometrial tissue has high steroid sulphatase (STS) activity. The aim of this study was to evaluate STS as a therapeutic target in patients with endometrial cancer.